Doyle Mittie 4

What Happened Doyle Mittie, a director of Cullinan Therapeutics (CGEM), was granted a derivative award on 2026-06-16 giving him the right to purchase 21,781 shares of common stock. The Form 4 reports the acquisition amount as $0.00 (derivative), indicating this was a grant of a purchase right — not an immediate purchase or sale of shares — and no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-16; Form 4 filed 2026-06-18 (filed timely).
• Reported transaction: Grant/award (derivative) of rights to 21,781 shares; reported price $0.00.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote (vesting): The option represents a right to purchase 21,781 shares that vests in full on the earlier of (i) June 16, 2027 or (ii) the issuer’s next annual meeting, subject to the Reporting Person’s continued service as a director.
• No exercise or sale reported — this is a compensatory grant, not an open-market trade.

Context This is a standard director equity award (a derivative grant subject to vesting) used for compensation and retention. Because the award vests in the future and was not exercised, it does not represent an immediate change in beneficial ownership or a market buy/sell signal. Retail investors should note such grants signal potential future dilution but do not on their own indicate the director bought or sold shares.